When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CLRB - Cellectar's lead asset shows 40% ORR in heavily pre-treated MM patients in mid-stage study
Cellectar Biosciences Inc.
Cellectar Biosciences (CLRB+2.8%) announced that a clinically meaningful 40% (6/15 patients) overall response rate (ORR) was observed in the CLOVER-1 Phase 2 study for CLR 131, in the subset of multiple myeloma (MM) patients, deemed triple class refractory who received a total administered dose of 60 mCi or greater.
More news on: Cellectar Biosciences, Inc., Healthcare stocks news,